References
- Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29:3559–3566.
- Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869–2879.
- Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
- van Vollenhoven RF, Emery P, Bingham CO 3rd, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013;72:1496–1502.
- Passalia C, Minetto P, Arboscello E, et al. Cardiovascular adverse events complicating the administration of rituximab: report of two cases. Tumori 2013;99:288e–292e.
- Rabinovitz A, Lombardo M, Schinke CD, et al. Rituximab and cardiotoxocity. J Am Coll Cardiol 2013;61.
- Kilickap S, Yavuz B, Aksoy S, et al. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma. Med Oncol 2008;25:437–442.
- Monsuez JJ, Charniot JC, Vignat N, et al. Cardiac side-effects of cancer chemotherapy. Int J Cardiol 2010;144:3–15.
- Gottdiener JS, Appelbaum FR, Ferrans VJ, et al Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981;141:758–763.
- Braverman AC, Antin JH, Plappert MT, et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991;9:1215–1223.
- Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009;27:1492–1501.
- Weide R, Hess G, Koppler H, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007;48:1299–1306.
- Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 2010;116: 106–114.
- Rasschaert M, Schrijvers D, Van den Brande J, et al. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors. Anticancer Drugs 2007;18: 587–595.